The neoadjuvant therapy of colorectal hepatic metastases and the role of biologic sensitizing and resistance factors

Journal of Surgical Oncology

Volumn 102, Issue 8, 2010, Pages 891-897

  Wanebo, Harold J ^a   Berz, David ^b  

^a Landmark Medical Center   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

anti angiogenesis; bevacizumab; cetuximab; colorectal cancer metastasis; EGFR directed therapy; liver metastasis; neoadjuvant therapy; panitumumab; tyrosine kinase inhibitors

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; CAPECITABINE; CELECOXIB; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; SORAFENIB; SUNITINIB; VANDETANIB;

ARTERY THROMBOSIS; CANCER SURVIVAL; COLORECTAL CANCER; DIGESTIVE SYSTEM PERFORATION; HEART INFARCTION; HUMAN; HYPERTENSION; LIVER METASTASIS; LIVER RESECTION; OVERALL SURVIVAL; PARTIAL HEPATECTOMY; PRIORITY JOURNAL; REVIEW; STROKE; WOUND HEALING;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; NEOADJUVANT THERAPY; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL ANALYSIS;

EID: 78650636536     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21691     Document Type: Review

References (73)

1. Riles LAG, Melbert D, Krapcho M, et al.: SEER Cancer Statistics Review, 1975-2005, National Cancer Institute. Bethesda, MD based on November 2007 SEER data submission. Ann Surg Oncol 2010; 17: 492.
2. Nordlinger B, Rougier P,: Liver metastases from colorectal cancer: The turning point. J Clin Oncol 2002; 20: 1442-1445. (Pubitemid 34260520)
3. Chua TC, et al.: Systematic review of randomized and nonrandomized trials of the clinical response and outcomes of neoadjuvant systemic chemotherapy for resectable colorectal liver metastases. Ann Surg Oncol 17: 492-501.
4. Andre T, et al.: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343-2351.
5. Douillard JY, et al.: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 2000; 355: 1041-1047.
6. Goldberg RM, et al.: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 23-30.
7. Bokemeyer C, et al.: Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009; 27: 663-671.
8. Hurwitz H, et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
9. Saltz LB, et al.: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol 2008; 26: 2013-2019.
10. Tanaka K, et al.: Role of neoadjuvant chemotherapy in the treatment of multiple colorectal metastases to the liver. Br J Surg 2003; 90: 963-969.
11. Adam R, et al.: Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol 2001; 8: 347-353.
12. Adam R, et al.: Tumor progression while on chemotherapy: A contraindication to liver resection for multiple colorectal metastases? Ann Surg 2004; 240: 1052-1061, discussion 1061-1064.
13. Nordlinger B, et al.: Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): A randomised controlled trial. Lancet 2008; 371: 1007-1016.
14. Adam R, et al.: Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: Myth or reality? J Clin Oncol 2008; 26: 1635-1641.
15. Gruenberger B, et al.: Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases. BMC Cancer 2008; 8: 120.
16. Blazer DG III, et al.: Pathologic response to preoperative chemotherapy: A new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol 2008; 26: 5344-5351.
17. Folkman J,: Angiogenesis: An organizing principle for drug discovery? Nat Rev Drug Discov 2007; 6: 273-286. (Pubitemid 46505878)
18. Gordon MS, et al.: Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001; 19: 843-850.
19. Olsson AK, et al.: VEGF receptor signalling-In control of vascular function. Nat Rev Mol Cell Biol 2006; 7: 359-371.
20. Fuchs CS, Marshall J, Barrueco J,: Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Updated results from the BICC-C study. J Clin Oncol 2008; 26: 689-690.
21. Hurwitz HI, et al.: Bevacizumab in combination with fluorouracil and leucovorin: An active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005; 23: 3502-3508.
22. Fuchs CS, et al.: Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Results from the BICC-C Study. J Clin Oncol 2007; 25: 4779-4786.
23. Kabbinavar FF, et al.: Combined analysis of efficacy: The addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005; 23: 3706-3712.
24. Okines A, et al.: Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial. Br J Cancer 2009; 101: 1033-1038.
25. Van Cutsem E, et al.: Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: The BEAT study. Ann Oncol 2009; 20: 1842-1847.
26. Tol J, Punt CJ,: Monoclonal antibodies in the treatment of metastatic colorectal cancer: A review. Clin Ther 2010; 32: 437-453.
27. Kopp R, et al.: Clinical implications of the EGF receptor/ligand system for tumor progression and survival in gastrointestinal carcinomas: Evidence for new therapeutic options. Recent Results Cancer Res 2003; 162: 115-132.
28. Damstrup L, et al.: Amphiregulin acts as an autocrine growth factor in two human polarizing colon cancer lines that exhibit domain selective EGF receptor mitogenesis. Br J Cancer 1999; 80: 1012-1019.
29. Rajaganeshan R, et al.: The influence of invasive growth pattern and microvessel density on prognosis in colorectal cancer and colorectal liver metastases. Br J Cancer 2007; 96: 1112-1117.
30. Fujisaki K, et al.: Circulating vascular endothelial growth factor in patients with colorectal cancer. Am J Gastroenterol 1998; 93: 249-252.
31. Jubb AM, et al.: Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol 2006; 24: 217-227.
32. Hyodo I, et al.: Clinical significance of plasma vascular endothelial growth factor in gastrointestinal cancer. Eur J Cancer 1998; 34: 2041-2045.
33. Huang N, et al.: Clinical significance of VEGF levels in serums of colorectal cancer patients at stage IV. Nan Fang Yi Ke Da Xue Xue Bao 2009; 29: 278-279.
34. Cunningham D, et al.: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345.
35. Chung KY, et al.: Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005; 23: 1803-1810.
36. Van Cutsem E, Lang I, D'haens G, et al.: KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience. J Clin Oncol 2008; 26: 2.
37. Elez E, Alsina M, Tabernero J,: Panitumumab-An effective long-term treatment for patients with metastatic colorectal cancer and wild-type KRAS status. Cancer Treat Rev 36: S15-S16.
38. Van Cutsem E, et al.: Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25: 1658-1664.
39. Jonker DJ, et al.: Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007; 357: 2040-2048.
40. Van Cutsem E, et al.: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-1417.
41. Amado RG, et al.: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626-1634.
42. Lopez-Crapez E, et al.: KRAS status analysis and anti-EGFR therapies: Is comprehensiveness a biologist's fancy or a clinical necessity? Br J Cancer 102: 1074-1075, author reply 1076-1077.
43. Andreyev HJ, et al.: Kirsten ras mutations in patients with colorectal cancer: The multicenter "RASCAL" study. J Natl Cancer Inst 1998; 90: 675-684.
44. Takayama T, et al.: Analysis of K-ras, APC, and beta-catenin in aberrant crypt foci in sporadic adenoma, cancer, and familial adenomatous polyposis. Gastroenterology 2001; 121: 599-611.
45. Vogelstein B, et al.: Genetic alterations during colorectal-tumor development. N Engl J Med 1988; 319: 525-532.
46. Rajagopalan H, et al.: Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002; 418: 934.
47. Bardelli A, Siena S,: Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 2010; 28: 1254-1261.
48. Laurent-Puig P, Cayre A, Pezet D, et al.: Analysis of PTEN, BRAF and EGFR status in determining benefit from cetuximab therapy in patients with metastatic colon cancer in wild-type KRAS patients. Annual Meeting of the American Association for Cancer Research, Denver, CO, 2009.
49. Pander J, et al.: Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer. Eur J Cancer.
50. Sartore-Bianchi A, et al.: PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 2009; 69: 1851-1857.
51. Laurent-Puig P, et al.: Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 2009; 27: 5924-5930.
52. Prenen H, et al.: PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clin Cancer Res 2009; 15: 3184-3188.
53. Frattini M, et al.: PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 2007; 97: 1139-1145.
54. Yamamoto H, Toyooka S, Mitsudomi T,: Impact of EGFR mutation analysis in non-small cell lung cancer. Lung Cancer 2009; 63: 315-321.
55. Barber TD, et al.: Somatic mutations of EGFR in colorectal cancers and glioblastomas. N Engl J Med 2004; 351: 2883.
56. Khambata-Ford S, et al.: Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007; 25: 3230-3237.
57. Shaheen RM, et al.: Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors. Br J Cancer 2001; 85: 584-589.
58. Tonra JR, et al.: Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy. Clin Cancer Res 2006; 12: 2197-2207.
59. Saltz LB, et al.: Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: The BOND-2 study. J Clin Oncol 2007; 25: 4557-4561.
60. Tol J, et al.: Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009; 360: 563-572.
61. Hecht JR, et al.: A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009; 27: 672-680.
62. Pohlmann PR, Mernaugh RL, Goff LW,: Chemotherapy and immunotherapy in metastatic colorectal cancer. N Engl J Med 2009; 360: 2134, author reply 2135-2136.
63. Deshaies I, et al.: Antiangiogenic agents and late anastomotic complications. J Surg Oncol 2010; 101: 180-183.
64. Rubbia-Brandt L, et al.: Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis. Histopathology 2010; 56: 430-439.
65. Klinger M, et al.: Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases. Eur J Surg Oncol 2009; 35: 515-520.
66. Khan AZ, Morris-Stiff G, Makuuchi M,: Patterns of chemotherapy-induced hepatic injury and their implications for patients undergoing liver resection for colorectal liver metastases. J Hepatobiliary Pancreat Surg 2009; 16: 137-144.
67. Saltz LB, et al.: Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol 2007; 25: 4793-4799.
68. Starling N, Cunningham D, Vazquez F, et al.: A phase I study of sunitinib in combination with FOLFIRI chemotherapy in treatment-naive, metastatic colorectal cancer. ASCO Gastrointestinal Cancers Symposium, 2007, abstract 319.
69. Walker T, et al.: Sorafenib and vorinostat kill colon cancer cells by CD95-dependent and -independent mechanisms. Mol Pharmacol 2009; 76: 342-355.
70. Michael M, Tebbutt N, Gibbs P, et al.: Vandetanib with mFOLFOX6 in advanced colorectal adenocarcinoma: An open-label multicenter phase I study. J Clin Oncol 2007; 25: 18.
71. Mross K, et al.: DCE-MRI assessment of the effect of vandetanib on tumor vasculature in patients with advanced colorectal cancer and liver metastases: A randomized phase I study. J Angiogenes Res 2009; 1: 5.
72. Gruenberger B, et al.: Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 2008; 26: 1830-1835.
73. Kesmodel SB, et al.: Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J Clin Oncol 2008; 26: 5254-5260.